Compare Gilead Sciences, Inc. (GILD) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Centrus Energy Corp — how do they compare? Gilead Sciences, Inc. trades at $135.67 (market cap $163.51B), while Centrus Energy Corp trades at $147.61 (market cap $3.08B). The key difference: Gilead Sciences, Inc. is far larger — about 53.1× Centrus Energy Corp's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals.
| GILD | LEU | |
|---|---|---|
Market Cap | $163.51B | $3.08B |
Sector | Health | Energy |
52-Week High | $155.80 | $436.00 |
52-Week Low | $108.22 | $146.61 |
Enterprise Value | $178.05B | $2.39B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Centrus Energy (LEU) trades at $145.80, down 8.52% on the day, showing technical weakness with bearish moving averages. The stock faces mixed fundamentals with recent earnings beats and misses, while benefiting from significant government contracts including a $1 billion DOE award. Valuation remains elevated with a P/E of 56.92, though analyst consensus maintains a $223.14 price target with 42% buy ratings. Recent developments include S&P SmallCap 600 inclusion and nuclear fuel supply agreements.
The outlook balances strong government backing and nuclear industry growth against high valuation and execution risks. Investment opportunity lies in LEU's unique position as the only licensed HALEU producer in the U.S., while risks include contract execution challenges and earnings volatility. The stock offers exposure to nuclear energy expansion but requires careful monitoring of profit margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
